Author Archive: BIOtechNOW Editor

Do Outcomes Matter When There Is Chronic Misalignment?

synthetic biology

This piece by Allan L. Shaw was originally published in Life Science Leader. With over $3 trillion in annual healthcare spending, a relatively young population, and shorter life expectancies than other western nations, one would think there would be vast opportunities for the U.S. healthcare industry to rein in costs, weed out inefficiency, and improve outcomes. Instead of yielding to “regression toward the mean,” however, the highest global per capita healthcare machine marches to 20 Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Emerging Themes in Personalized Medicine

1500x500

The adoption of Personalized Medicine is being driven by the omnipresence of Next-Generation Sequencing (NGS), the fast pace of technological innovations in the field, and the President’s Precision Medicine Initiative. To date, however, only a relatively small fraction of the patient population has had their DNA fully sequenced, while a larger segment has undergone limited analysis related to an NGS-based diagnostics test, primarily in the area of oncology. It is expected that this picture will Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Biopharma Companies Fight Tropical Diseases to Improve Global Health

International

Neglected tropical diseases (NTDs) are a group of devastating viral, bacterial, and parasitic diseases that predominantly burden individuals and communities living in poverty. NTDs received the moniker “neglected” due to the lack of attention they have received from the global biopharmaceutical community, and the resultant dearth of products available to prevent, diagnose, and treat them. This has been changing, though – Knight Therapeutics Inc. developed a drug to treat leishmaniasis (Impavido®) in 2014, Sanofi Pasteur Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Biomarkets: Looking For The Hole In The Donut

synthetic biology

This piece by Allan L. Shaw was originally published in Life Science Leader. The biopharma sector has enjoyed increased market success over the last few years. And while some may be tempted to bask in the optimistic “bio-euphoria,” others question whether the industry might be in the midst of a market bubble. What led to this current period of biopharma success, despite the industry’s inherent risks (e.g. scientific, clinical, regulatory, and commercial)? Several factors contributed Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Why I packed my bag and headed to NASDA 2015 in Hawaii

Lorie Farrell

As the head wrangler and ringleader for Hawaii Farmers & Ranchers United, an agriculture alliance based on Hawaii Island, it made sense to go and show support for Scott Enright; Hawaii’s Chair of the Department of Agriculture. It would have been remiss to pass up this opportunity to attend this annual convention full of Agriculture thought leaders. Due to the cost I had only planned on attending for one day but fate intervened and I Read More >

Food And Agriculture  |  Leave a comment  |  Email This Post
Tags: , , ,